The goal of this clinical trial is to determine if the combination of venetoclax, daratumumab and dexamethasone (with or without bortezomib) is safe and tolerable in patients with relapsed or refractory multiple myeloma.
SparkCures ID | 923 |
---|---|
Trial Phase | Phase 1/2 |
Enrollment | 156 Patients |
Treatments |
|
Tags | |
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Exclusion Criteria:
For participants in Parts 1 and 2: Previous treatment with daratumumab or other anti-CD38 therapy. For participants in Part 3: Prior daratumumab or other anti-CD38 antibody therapy exposure that meets ANY of the following criteria:
For participants in Part 2 and 3:
History of other active malignancies including myelodysplatic syndromes (MDS) within the past 3 years with the exceptions of:
Please visit the ClinicalTrials.gov page for historical site information.
View CentersSparkCures is working closely with AbbVie to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.
Learn more about how we work with trial sponsors